About HYLENEX® recombinant (hyaluronidase) injection

Indication:

HYLENEX recombinant is an endoglycosidase indicated as an adjuvant to increase the dispersion and absorption of other injected drugs.

Important Safety Information:

Contraindications

HYLENEX recombinant is contraindicated in patients with known hypersensitivity to hyaluronidase or any of the excipients in HYLENEX recombinant. Discontinue HYLENEX recombinant if sensitization occurs.

Warnings and Precautions

Spread of Localized Infection: Hyaluronidase should not be injected into or around an infected or acutely inflamed area because of the danger of spreading a localized infection.

Ocular Damage: Hyaluronidase should not be applied directly to the cornea. It is not for topical use.

Important Administration Instructions

Enzyme Inactivation with Intravenous Administration: HYLENEX recombinant should not be used for intravenous administration because the enzyme is rapidly inactivated.

Adverse Reactions

Allergic reactions have been reported in less than 0.1% of patients receiving hyaluronidase. Anaphylactic-like reactions following retrobulbar block or intravenous injections have occurred, rarely. The most frequently reported adverse reactions have been mild local injection site reactions, such as erythema and pain. Hyaluronidase has been reported to enhance the adverse reactions associated with coadministered drug products.

Drug Interactions

Furosemide, the benzodiazepines, products containing sodium metabisulfite (e.g., in local anesthetic products containing epinephrine) and phenytoin are incompatible with hyaluronidase. Hyaluronidase should not be used to enhance the dispersion and absorption of dopamine and/or alpha agonist drugs. When used with local anesthetics, hyaluronidase hastens the onset of analgesia and shortens its duration of action and tends to increase the incidence of systemic reactions. Patients receiving large doses of salicylates, cortisone, ACTH, estrogens or antihistamines may require larger amounts of hyaluronidase for equivalent dispersing effect.

You may report an adverse event related to Hylenex recombinant by calling 1-877-877-1679. If you prefer, you may contact the FDA directly.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see the Full Prescribing Information.

*Monthly hyaluronidase market share based on DDD® Non-Retail Sales Data from IQVIA® (May 2013-March 2024).